Search research articles
Contact Us
Filters
Showing results (331-340 of 508) with videos related to
Page
of 51
Sort By:
The Journal of Antimicrobial Chemotherapy
|
August 28, 2014
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202
Charles S Venuto, Katie Mollan, Qing Ma, et al.
Annals of Internal Medicine
|
January 1, 1995
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group
M A Fischl, K Stanley, A C Collier, et al.
Journal of the International Association of Providers of AIDS Care
|
March 9, 2021
"Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya
Jane M Simoni, Kristin Beima-Sofie, George Wanje, et al.
AJNR. American Journal of Neuroradiology
|
July 11, 1992
Prospective cerebral MR study of HIV seropositive and seronegative men: correlation of MR findings with neurologic, neuropsychologic, and cerebrospinal fluid analysis
W A Cohen, K R Maravilla, R Gerlach, et al.
Molecular Ecology
|
November 18, 2018
The fate of genes that cross species boundaries after a major hybridization event in a natural mosquito population
Mark J Hanemaaijer, Travis C Collier, Allison Chang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 1, 1993
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
E L Cooney, M J McElrath, L Corey, et al.
The Journal of Infectious Diseases
|
August 19, 2000
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333
M F Para, D V Glidden, R W Coombs, et al.
AIDS (London, England)
|
August 28, 2007
The prevalence and incidence of neurocognitive impairment in the HAART era
Kevin R Robertson, Marlene Smurzynski, Thomas D Parsons, et al.
AIDS Care
|
January 25, 2021
Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings
Thiago S Torres, Linda J Harrison, Alberto M La Rosa, et al.
AIDS (London, England)
|
January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
Margaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Page
of 51
Search research articles
Search
Showing results (331-340 of 508) with videos related to
Sort By:
Page
of 51
The Journal of Antimicrobial Chemotherapy
|
August 28, 2014
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202
Charles S Venuto, Katie Mollan, Qing Ma, et al.
Annals of Internal Medicine
|
January 1, 1995
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group
M A Fischl, K Stanley, A C Collier, et al.
Journal of the International Association of Providers of AIDS Care
|
March 9, 2021
"Lighten This Burden of Ours": Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya
Jane M Simoni, Kristin Beima-Sofie, George Wanje, et al.
AJNR. American Journal of Neuroradiology
|
July 11, 1992
Prospective cerebral MR study of HIV seropositive and seronegative men: correlation of MR findings with neurologic, neuropsychologic, and cerebrospinal fluid analysis
W A Cohen, K R Maravilla, R Gerlach, et al.
Molecular Ecology
|
November 18, 2018
The fate of genes that cross species boundaries after a major hybridization event in a natural mosquito population
Mark J Hanemaaijer, Travis C Collier, Allison Chang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 1, 1993
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
E L Cooney, M J McElrath, L Corey, et al.
The Journal of Infectious Diseases
|
August 19, 2000
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333
M F Para, D V Glidden, R W Coombs, et al.
AIDS (London, England)
|
August 28, 2007
The prevalence and incidence of neurocognitive impairment in the HAART era
Kevin R Robertson, Marlene Smurzynski, Thomas D Parsons, et al.
AIDS Care
|
January 25, 2021
Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings
Thiago S Torres, Linda J Harrison, Alberto M La Rosa, et al.
AIDS (London, England)
|
January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
Margaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Page
of 51